For most of modern psychiatry’s existence, clinicians have been handing patients the same basic categories of medication (SSRIs, SNRIs, benzodiazepines, antipsychotics) and hoping one sticks. Try a pill, wait six weeks, feel weird, try another, wait six more weeks, feel different-weird. It helps a lot of people, but for treatment-resistant depression, the kind that doesn’t respond to at least two adequate trials of antidepressants, we’ve been playing darts in a dark room for decades.
On April 24th, the FDA granted priority review vouchers to three companies developing psychedelic-based treatments: Compass Pathways for psilocybin in treatment-resistant depression, the Usona Institute for psilocybin in major depressive disorder, and Transcend Therapeutics for methylone (a chemical cousin of MDMA) in PTSD. This followed a presidential executive order accelerating psychedelic research with $50 million in funding attached. The review timeline just went from 12-plus months to potentially one or two months after application filing.
What the data actually shows
Compass Pathways ran a phase 3 trial with over 1,000 participants, all people for whom the standard playbook had already failed. Patients experienced measurable improvement within a day of a single psilocybin session, and those who responded maintained that response for at least six months. One session. Six months. Compare that to a daily SSRI that takes six weeks to kick in and stops working the moment it’s discontinued. The effect sizes are better than what we see for most psychiatric medications already on the market. The numbers are hard to argue with.
Caveats matter. Not everyone responded, and we’re still early in understanding who benefits most and why.
Why this took so long
There’s a concept in economics called path dependence, where decisions made in the past constrain future options even when those original decisions no longer make sense. Psychedelics have been stuck in their own path dependence since 1970, when the Controlled Substances Act classified psilocybin as Schedule I, the same category as heroin. This happened because of cultural panic, not clinical evidence. Timothy Leary, the counterculture, Vietnam protests. The drugs became politically radioactive, and promising research from the 1950s was abandoned. For 40-plus years, no one could study them because they were Schedule I, and they stayed Schedule I because no one had recent data to justify reclassification. A self-fulfilling prophecy.
The honest concerns
Both the psychedelic evangelists and the skeptics are making predictable mistakes. The evangelists treat these compounds like a spiritual cheat code: one session and depression evaporates, trauma resolves, the universe reveals itself. This is naive. Psychedelic experiences can be destabilizing for people who aren’t adequately prepared. They can trigger psychotic episodes in vulnerable individuals. The therapist-assisted model these trials use has nothing in common with someone’s buddy handing them mushrooms at a music festival.
The skeptics dismiss the entire field because it sounds like hippie nonsense. Equally naive, just in the opposite direction. These compounds demonstrably alter serotonin 2A receptor activity, promote neuroplasticity, and disrupt the default mode network, the brain circuitry behind rumination and the rigid mental loops that characterize depression. Dismissing all of that because the drugs have a countercultural history is like refusing to use aspirin because willow bark was once folk medicine.
The real concern is access. These treatments require trained therapists, controlled settings, hours of preparation and integration. How do we scale that to millions of Americans with treatment-resistant depression? How do we prevent the corner-cutting that happens when a massive market meets a bottleneck of qualified providers?
What this means right now
For anyone struggling with depression or PTSD that hasn’t responded to traditional treatment, this is genuinely encouraging, but not a reason to seek out psilocybin independently. The therapeutic context matters enormously. It is, however, a reason to talk to a psychiatrist about what’s coming. Ask about clinical trials, about ketamine or esketamine (already FDA-approved), and about the integrative foundations of therapy, exercise, sleep, and nutrition that any good treatment should be built on.
We’re watching what might be the most significant shift in psychiatric treatment in a generation. It won’t be clean, and there will be plenty of hype to wade through. But for the first time in a long time, there’s real, well-funded, federally backed science pointed at something genuinely new for the people who need it most.
– Delos